+Compare
CANF
Stock ticker: NASDAQ
AS OF
Loading...
Price
Loading...
Change
Loading...
Capitalization
8.84M

CANF Can-Fite BioPharma Ltd Forecast, Technical & Fundamental Analysis

a developer of biopharmaceuticals for treatment of autoimmune diseases and cancers

Industry Biotechnology
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
A.I.Advisor
a Summary for CANF with price predictions
07:00 PM EST Dec 05, 2023

CANF in upward trend: 10-day moving average crossed above 50-day moving average on December 01, 2023

The 10-day moving average for CANF crossed bullishly above the 50-day moving average on December 01, 2023. This indicates that the trend has shifted higher and could be considered a buy signal. In of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where CANF's RSI Oscillator exited the oversold zone, of 42 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 67 cases where CANF's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on November 24, 2023. You may want to consider a long position or call options on CANF as a result. In of 90 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for CANF just turned positive on November 01, 2023. Looking at past instances where CANF's MACD turned positive, the stock continued to rise in of 45 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CANF advanced for three days, in of 206 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 111 cases where CANF Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

CANF moved below its 50-day moving average on December 06, 2023 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CANF declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

CANF broke above its upper Bollinger Band on November 27, 2023. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

Fear & Greed

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.390) is normal, around the industry mean (20.694). P/E Ratio (0.000) is within average values for comparable stocks, (137.286). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (7.704). Dividend Yield (0.000) settles around the average of (0.035) among similar stocks. P/S Ratio (9.921) is also within normal values, averaging (329.913).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. CANF’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CANF’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), Incyte Corp (NASDAQ:INCY), Sarepta Therapeutics (NASDAQ:SRPT), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), BioCryst Pharmaceuticals (NASDAQ:BCRX), Novavax (NASDAQ:NVAX), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Sorrento Therapeutics, Inc. (OTC:SRNEQ).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.3B. The market cap for tickers in the group ranges from 402 to 464.61B. NVO holds the highest valuation in this group at 464.61B. The lowest valued company is PNEXF at 402.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was 7%. For the same Industry, the average monthly price growth was 6%, and the average quarterly price growth was 28%. IVBT experienced the highest price growth at 1,413%, while TMBRQ experienced the biggest fall at -94%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -41%. For the same stocks of the Industry, the average monthly volume growth was -36% and the average quarterly volume growth was 3%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 85
Price Growth Rating: 64
SMR Rating: 94
Profit Risk Rating: 94
Seasonality Score: 27 (-100 ... +100)
View a ticker or compare two or three
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Ad is loading...
A.I. Advisor
published Earnings

CANF is expected to report earnings to rise 500.00% to -5 cents per share on November 26

Can-Fite BioPharma Ltd CANF Stock Earnings Reports
Q3'18
Est.
$-0.06
Q3'22
Beat
by $0.08
Q2'22
Beat
by $0.04
Q1'22
Beat
by $0.14
Q4'21
Missed
by $0.13
The last earnings report on November 25 showed earnings per share of 0 cents, beating the estimate of -9 cents. With 70.44K shares outstanding, the current market capitalization sits at 8.84M.
A.I. Advisor
published General Information

General Information

a developer of biopharmaceuticals for treatment of autoimmune diseases and cancers

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
10 Bareket Street, Kiryat Matalon
Phone
+972 39241114
Employees
8
Web
http://www.canfite.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
CAG29.410.65
+2.24%
Conagra Brands
MTEK1.020.02
+1.67%
Maris-Tech Ltd
AMAM12.03-0.07
-0.58%
Ambrx Biopharma
AIR69.21-0.75
-1.07%
AAR Corp
AQST2.06-0.31
-13.08%
Aquestive Therapeutics

CANF and

Correlation & Price change

A.I.dvisor indicates that over the last year, CANF has been loosely correlated with ALDX. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if CANF jumps, then ALDX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CANF
1D Price
Change %
CANF100%
-3.56%
ALDX - CANF
46%
Loosely correlated
+1.29%
DBVT - CANF
37%
Loosely correlated
+4.02%
TPST - CANF
27%
Poorly correlated
-3.11%
BCEL - CANF
26%
Poorly correlated
+0.45%
ARWR - CANF
25%
Poorly correlated
+1.54%
More

Groups containing CANF

Correlation & Price change

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CANF
1D Price
Change %
CANF100%
-3.56%
middle east
(undefined stocks)
14%
Poorly correlated
-0.59%
biotechnology
(undefined stocks)
11%
Poorly correlated
+1.69%
drugs
(undefined stocks)
11%
Poorly correlated
+1.31%
diseases
(undefined stocks)
8%
Poorly correlated
+0.08%
biopharmaceuticals
(undefined stocks)
8%
Poorly correlated
+1.69%
More